Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: Neurocrine Biosciences, Inc. discovers, develops, and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company?s products in clinical development stage include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for tourette syndrome schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for men?s and women?s health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other con
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-11.83%||ROE||-12.96%||ROI|
|Current Ratio||22.19||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.04|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||275.28 M||Cash From Investing Activities||-170.01 M||Cash From Operating Activities||-4.22 M||Gross Profit|
|Net Profit||-23.99 M||Operating Profit||-25.32 M||Total Assets||511.2 M||Total Current Assets||389.42 M|
|Total Current Liabilities||17.55 M||Total Debt||560 K||Total Liabilities||44.27 M||Total Revenue|
|High 52 week||125.85||Low 52 week||68.32||Last close||79.03||Last change||-1.21%|
|RSI||54.59||Average true range||3.18||Beta||1.39||Volume||828.99 K|
|Simple moving average 20 days||1.06%||Simple moving average 50 days||-4.52%||Simple moving average 200 days||-16.4%|
|Performance Week||0.29%||Performance Month||-2.6%||Performance Quart||-6.27%||Performance Half||-20.57%|
|Performance Year||-15.81%||Performance Year-to-date||10.67%||Volatility daily||2.49%||Volatility weekly||5.58%|
|Volatility monthly||11.43%||Volatility yearly||39.6%||Relative Volume||252.57%||Average Volume||908.6 K|
|New High||New Low|
2019-06-18 08:03:56 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-06-13 08:04:47 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-06-11 13:49:27 | Hedge Funds Are Dumping Neurocrine Biosciences, Inc. NBIX
2019-06-10 08:04:49 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-06-08 08:04:18 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-06-04 08:02:33 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-05-31 11:51:46 | Is Neurocrine Biosciences, Inc. NASDAQ:NBIX Trading At A 30% Discount?
2019-05-30 16:01:00 | Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference
2019-05-29 09:15:01 | Not Ready to Rally
2019-05-20 08:00:00 | Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life
2019-05-16 16:01:00 | Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting
2019-05-08 09:15:01 | Trade Anxieties Return with a Vengeance
2019-05-07 08:02:32 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-05-05 09:00:00 | Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations
2019-04-30 17:36:26 | Edited Transcript of NBIX earnings conference call or presentation 29-Apr-19 8:30pm GMT
2019-04-30 10:35:02 | Neurocrine Biosciences Has Robust Late-Stage Pipeline
2019-04-30 09:01:20 | What Are Analysts Recommending for NBIX after Q1 Results?
2019-04-29 22:38:43 | Neurocrine Biosciences Inc NBIX Q1 2019 Earnings Call Transcript
2019-04-29 16:15:23 | Neurocrine: 1Q Earnings Snapshot
2019-04-29 16:01:00 | Neurocrine Biosciences Reports First Quarter 2019 Financial Results
2019-04-26 06:10:23 | Analysts point to potential Biogen M&A options after Alzheimer's failure
2019-04-20 20:24:44 | Did Hedge Funds Drop The Ball On Neurocrine Biosciences, Inc. NBIX ?
2019-04-16 11:31:26 | Is Neurocrine Biosciences, Inc. NASDAQ:NBIX A Financially Sound Company?
2019-04-09 10:47:53 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-04-02 11:52:47 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-04-01 07:45:00 | Recent Analysis Shows Coca-Cola, Neurocrine Biosciences, Worthington Industries, Lennox International, Barrett Business Services, and Balchem Market Influences — Renewed Outlook, Key Drivers of Growth
2019-03-29 09:33:12 | Analysts Raise Neurocrine Biosciences’ Target Price in March
2019-03-26 08:25:02 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-03-23 10:02:00 | 2 Biotech Takeout Targets Perfect for Biogen
2019-03-20 10:43:28 | Sage Stock Pops on FDA Approval for Postpartum Depression Drug
2019-03-15 09:30:01 | CTLT or NBIX: Which Is the Better Value Stock Right Now?
2019-03-07 09:15:02 | Stocks Slide for Third Straight Day
2019-03-05 16:01:00 | Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2019-03-05 08:01:53 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
2019-03-01 12:33:17 | Why These 2 Biotech Stocks Might Be Next On The Takeover List
2019-02-28 11:56:07 | Why Neurocrine Biosciences, Inc. NASDAQ:NBIX Is An Attractive Investment To Consider
2019-02-22 11:31:07 | Voyager Therapeutics stock jumps on 2nd Parkinson's deal
2019-02-12 09:30:02 | CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?
2019-02-08 08:05:10 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.